You are here

P&T® Journal contents for October 2006


Letter to the Editor
Joe Jeffries, RPh
The authors conducted a retrospective cohort study at their institution to determine the inpatient care cost of treating candidemia, the leading cause of fungal infections in hospitalized patients.
Joshua J. Gagne, PharmD, Ross E. Breitbart, MS, Vittorio Maio, PharmD, MS, MSPH, David L. Horn, MD, Christine W. Hartmann, MSS, PhD, Robert Swanson, PhD, and Neil I. Goldfarb
The authors present the findings of a study that was designed to compare the effectiveness and equivalence of two erythropoietic agents based on a randomized, prospective clinical trial.
Antoine Gosselin, MA, R. Scott McKenzie, MD, Patrick Lefebvre, MA, Samir H. Mody, PharmD, MBA, Catherine Tak Piech, MBA, and Mei Sheng Duh, MPH, ScD
Continuing Education Credit
In multiple trials and analyses, the incidence of cardiovascular events has been higher with coxibs than with placebo and other nonselective NSAIDs. Although an explanation for these events has not yet been determined, several theories relate to physiological mechanisms, drug selectivity or structure, doses and duration of clinical trials, and the influence of underlying disease states.
Craig D. Cox, PharmD, BCPS, Brad L. Stanford, PharmD, BCOP, James P. Tsikouris, PharmD, Michael J. Peeters, PharmD, BCPS, and Gary Meyerrose, MD


David Nash, MD, MBA, illustrates the importance of one executive’s commitment to developing new leaders and emphasizes the need for the health care industry to recognize this challenge.
David Nash, MD, MBA
Prescription: Washington
Stephen Barlas explains a new FDA anti-counterfeiting measure that will require pharmacies to obtain a drug “pedigree” from wholesalers who are not authorized distributors.
Stephen Barlas
Medication Errors
Matthew Grissinger, RPh, FASCP, discusses the technology of “smart” infusion pumps that will aid hospitals in the effort to reduce mistakes.
Matthew Grissinger, RPh, FASCP
P&T presents the latest information about FDA approvals, drug indications, industry updates, and new devices.
Drug Forecast
The authors review pregabalin (Lyrica) for neuropathic pain and partial seizures.
Jason N. Roe, PharmD, Edanai M. Velez, PharmD Candidate, and Jose A. Rey, PharmD